August 28, 2024

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Hagiwara et al. (Wed,) studied this question.

synapsesocial.com/papers/68e5a81fb6db643587542a1f https://doi.org/https://doi.org/10.21873/anticanres.17235

Preguntar a la IA

Me gusta

Guardar